Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells

Biotechnology Journal

Volumn 5, Issue 4, 2010, Pages 377-384

  Mazars, Anne ^a   Fåhraeus, Robin ^a  

^a INSERM   (France)

Author keywords

Bioluminescence resonance energy transfer; Drug development; HDM2; Methods; P53

Indexed keywords

BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL-BASED; DRUG DESIGN; DRUG DEVELOPMENT; HYDROPHOBIC POCKETS; IN-VITRO; IN-VIVO; LIVE CELL; LIVING CELL; MODEL SYSTEM; PROTEIN INTERACTION; PROTEIN-PROTEIN INTERACTIONS; SCREENING ASSAYS; TUMOR SUPPRESSORS; UBIQUITIN LIGASES;

BIOLUMINESCENCE; CHEMICAL COMPOUNDS; CHEMICALS; ENERGY TRANSFER; PHOSPHORESCENCE; PROTEINS; RESONANCE;

DRUG INTERACTIONS;

CHEMICAL COMPOUND; HYBRID PROTEIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL CULTURE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MUTAGENESIS; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; WESTERN BLOTTING;

FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950653875     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200900272     Document Type: Article

References (12)

1. van Montfort, R. L., Workman, P., Structure-based design of molecular cancer therapeutics. Trends Biotechnol. 2009, 27, 315-328.
2. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B. et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1031-1037.
3. Milligan, G., Applications of bioluminescence- and fluorescence resonance energy transfer to drug discovery at G protein-coupled receptors. Eur. J. Pharm. Sci. 2004, 21, 397-405.
4. Bacart, J., Corbel, C., Jockers, R., Bach, S., Couturier, C., The BRET technology and its application to screening assays. Biotechnol. J. 2008, 3, 311-324.
5. Kasprzak, A. A., The use of FRET in the analysis of motor protein structure. Methods Mol. Biol. 2007, 392, 183-197.
6. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B. et al., Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
7. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D. et al., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
8. Storez, H., Scott, M. G., Issafras, H., Burtey, A. et al., Homo- and hetero-oligomerization of beta-arrestins in living cells. J. Biol. Chem. 2005, 280, 40210-40215.
9. Yin, Y., Stephen, C. W., Luciani, M. G., Fahraeus, R., p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat. Cell Biol. 2002, 4, 462-467.
10. Wallace, M., Worrall, E., Pettersson, S., Hupp, T. R., Ball, K. L., Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 2006, 23, 251-263.
11. Pommier, Y., Cherfils, J., Interfacial inhibition of macromolecular interactions: Nature's paradigm for drug discovery. Trends Pharmacol. Sci. 2005, 26, 138-145.
12. Berg, T., Inhibition of transcription factors with small organic molecules. Curr. Opin. Chem. Biol. 2008, 12, 464-471.